Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study

Journal of Clinical Pharmacology
Masahiko Gosho

Abstract

Hypoglycemia is the most important complication of antidiabetic medications. Most patients with diabetes mellitus take multiple medications. In this study, we explored clinical drug-drug interactions that result in hypoglycemia by analyzing the Japanese Adverse Drug Event Report (JADER) database. The primary outcome was the report of hypoglycemia. The Norén and Gosho methods, which quantitatively measure the discrepancy between the observed and expected number of adverse events under the combination of 2 drugs, were used as the criteria for detecting drug-drug interactions. The JADER database contained patient characteristics with 468 292 records, drug information with 2 973 172 records, and adverse reactions with 741 016 records. We noted that hypoglycemia was reported in 6208 patients. Concomitant use of linagliptin/glibenclamide, sitagliptin/glibenclamide, sitagliptin/buformin, exenatide/voglibose, mitiglinide/perindopril, repaglinide/barnidipine, alogliptin/cilnidipine, teneligliptin/barnidipine, teneligliptin/urapidil, exenatide/candesartan, voglibose/barnidipine, voglibose/guanabenz, or exenatide/tocopherol was noted using the 2 criteria for drug-drug interactions. Concomitant use of teneligliptin and barnidipine produced...Continue Reading

References

May 1, 1985·Annals of Neurology·R Malouf, J C Brust
Dec 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·D TessierG S Meneilly
Aug 11, 1998·European Journal of Clinical Pharmacology·A BateR M De Freitas
Feb 16, 1999·Archives of Internal Medicine·H Ben-AmiY Edoute
Jul 27, 1999·British Journal of Clinical Pharmacology·M Collin, J C Mucklow
May 27, 2003·Diabetes Care·Philip E CryerHarry Shamoon
Nov 14, 2003·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·A Holstein, E-H Egberts
Aug 19, 2004·Pharmacoepidemiology and Drug Safety·Kenneth J RothmanSusan T Sacks
Jun 21, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Mar 18, 2008·Statistics in Medicine·G Niklas NorénI Ralph Edwards
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Aug 9, 2008·Clinical Interventions in Aging·Reamer L BushardtKit N Simpson
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Jan 1, 2012·Journal of Diabetes and Metabolic Disorders·Gita ShafieeBagher Larijani
May 3, 2013·Vascular Health and Risk Management·Bo Ahrén
Mar 31, 2015·Clinical Pharmacology and Therapeutics·C J Bailey
Jul 1, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Mar 11, 2017·European Journal of Clinical Pharmacology·Masahiko GoshoAkihiro Hirakawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

© 2022 Meta ULC. All rights reserved